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Summary
 
Interferon regulatory factor-1 (IRF-1) is a transcription factor that regulates interferon-induced
genes and type I interferons. Recently, studies of IRF-1-deficient mice have revealed that
IRF-1 regulates the induction of molecules that play important roles in inflammation, such as
inducible nitric oxide synthase (iNOS) and interleukin-1
 
b
 
-converting enzyme (ICE). To study
the role of IRF-1 in autoimmunity, we investigated type II collagen-induced arthritis (CIA),
and experimental allergic encephalomyelitis (EAE), in mice lacking IRF-1. The incidence and
severity of CIA were significantly decreased in IRF-1
 
2
 
/
 
2
 
 mice compared with IRF-1
 
1
 
/
 
2
 
 mice,
as was the production of interferon (IFN)-
 
g
 
 in lymph node cells. Both IRF-1
 
1
 
/
 
2
 
 and IRF-1
 
2
 
/
 
2
 
mice exhibited mild and transient disease after adoptive transfer of a type II collagen (CII)-spe-
cific T cell line together with sera from arthritic mice, but the IRF-1
 
2
 
/
 
2
 
 mice were less se-
verely affected than the IRF-1
 
1
 
/
 
2
 
 mice. In addition, the incidence of EAE in IRF-1
 
2
 
/
 
2
 
 mice
was decreased as compared with IRF-1
 
1
 
/
 
2
 
 mice. Reverse transcription polymerase chain reac-
tion showed that IRF-1 mRNA was constitutively expressed in the spinal cords of IRF-1
 
1
 
/
 
2
 
mice, and was upregulated in mice with clinical EAE. Expression of iNOS was also detected in
inflamed spinal cords. These results suggest that IRF-1 plays a key role in promoting inflamma-
tion and autoimmunity in CIA and EAE animal models.
 
I
 
nterferon regulatory factor 1 (IRF-1)
 
1
 
 was originally iden-
tified as a transcriptional activator of type I IFN (1, 2). It
binds to IRF-E sequence elements in DNA, which overlap
the IFN-stimulated response element (ISRE) (3–5). Re-
cently, studies of IRF-1-deficient mice constructed with
gene targeting (6) have revealed that IRF-1 has additional
important functions, including that of tumor suppression
(7, 8). Kamijo et al. (9) and others (10, 11) have reported
that the induction of inducible nitric oxide synthase (iNOS)
in macrophages is dependent on IRF-1.
Nitric oxide (NO) has numerous known functions in a
variety of tissues, including activities against tumors and
microorganisms (12). The transient high level of produc-
tion of NO by iNOS in macrophages and other cells has
been shown to be an important factor in host defense
against bacteria, inflammatory responses, and endotoxin
shock (13, 14). Furthermore, a role for NO in murine and
rat autoimmune disease models has been suggested (15–20).
The finding that IRF-1 controls the induction of iNOS
suggested the possibility that iNOS induction and subse-
quent NO secretion might be modified by manipulating
the function or induction of IRF-1. It has recently been es-
tablished that IL-1
 
b
 
 convertase (ICE) is also regulated by
IRF-1 (21). ICE is important in IL-1 secretion, as well as in
cell death induction (22, 23). These studies prompted us to
investigate whether IRF-1 is involved in the pathogenesis
of inflammation and autoimmune disease.
In this study, we used IRF-1-deficient mice to investi-
gate the role of IRF-1 in collagen-induced arthritis (CIA),
and in experimental allergic encephalomyelitis (EAE). Our
results indicate that IRF-1
 
2
 
/
 
2
 
 mice exhibit significantly de-
creased incidence and severity of both diseases, particularly
CIA. Reverse transcription studies (RT-PCR) showed that
IRF-1 mRNA was constitutively expressed in the spinal
cord and that its expression was further enhanced after the
onset of EAE. IRF-1 mRNA expression also correlated
with the expression of iNOS found in inflamed spinal cords
of IRF-1
 
1
 
/
 
2
 
 mice with clinical EAE.
 
1
 
Abbreviations used in this paper:
 
 CIA, collagen-induced arthritis; CII, type
II collagen; EAE, experimental allergic encephalomyelitis; ICE, interleu-
kin-1
 
b
 
-converting enzyme; iNOS, inducible nitric oxide synthase; IRF-1,
interferon regulatory factor-1; ISRE, IFN-stimulated response element;
NO, nitric oxide; NOD, nonobese diabetes.
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Materials and Methods
 
Mice.
 
To generate mice with an MHC haplotype susceptible
to CIA or EAE, IRF-1
 
2
 
/
 
2
 
 mice (5) were back-crossed into
DBA/1 (H-2
 
q
 
) or PL/J (H-2
 
u
 
) mice and the fourth generation
(DBA/1), or the second and the third generation (PL/J), of mice
were used for experiments. Mice were typed by PCR or South-
ern blot (5) during back-crossing. Homozygous (IRF-1
 
2
 
/
 
2
 
) mice
were obtained by intercrossing IRF-1
 
1
 
/
 
2
 
 mice. IRF-1
 
1
 
/
 
2
 
 and
IRF-1
 
2
 
/
 
2
 
 mice were mated and progeny littermates were ana-
lyzed for CD8
 
1
 
 T cell populations in peripheral blood using flow
cytometry (5). CD8
 
1
 
 T cell populations were as follows: IRF-1
 
1
 
/
 
2
 
DBA/1, 15.1–35.0% (of CD3
 
1
 
 cells); IRF-1
 
2
 
/
 
2
 
 DBA/1, 3.1–
10.2%; IRF-1
 
1
 
/
 
2
 
 PL/J, 19.5–34.6%; IRF-1
 
2
 
/
 
2
 
 PL/J: 3.8–11.2%.
In all experiments, only IRF-1
 
1
 
/
 
2
 
 littermates were used as con-
trols. All mice were 8–16 wk of age at the time of immunization
and were maintained at the Ontario Cancer Institute Animal Fa-
cility. Animals were cared for in accordance with the guidelines
of the Canadian Medical Research Council.
 
Induction of CIA.
 
Mice were immunized intradermally at the
base of the tail with 150 
 
m
 
g bovine collagen type II (CII) (Elastin
Products, Owensville, MO) emulsified with an equal volume of
CFA, containing 200 
 
m
 
g of H37RA 
 
Mycobacterium tuberculosis
 
(Difco, Detroit, MI). Mice were boosted by intradermal injection
with 150 
 
m
 
g bovine CII in IFA on day 21. Arthritis development
was monitored by inspection three times per week and inflamma-
tion of the four paws was graded from 0 to 3 as follows: grade 0,
paws with no swelling; grade 1, paws with swelling of finger
joints or mild swelling of ankle or wrist joints; grade 2, paws with
severe inflammation of the entire paw; grade 3, paws with defor-
mity or ankylosis. Each paw was graded and the four scores added
so that the maximum score per mouse was 12. The arthritis index
was calculated by dividing the total score of the experimental
mice by the total number of arthritic mice. Parameters used to as-
sess arthritis in each group were disease incidence, arthritis index,
and the number of arthritic paws.
 
Measurement of Serum Anti-CII Antibody Levels.
 
The level of
serum antibodies to CII was measured by ELISA. Native bovine
CII was dissolved in 0.1 M acetic acid at 1 mg/ml and diluted
with 0.1 M sodium bicarbonate at 10 
 
m
 
g/ml. Microtiter plates
(Maxisorp, Nunc, Denmark) were coated with 100 
 
m
 
l of CII an-
tigen solution and incubated overnight at 4
 
8
 
C. After washing
with PBS containing 0.05% Tween 20, nonspecific binding was
blocked with PBS containing 1% bovine serum albumin for 1 h
at room temperature. After two washes, serum samples were
added in serial dilutions and incubated for 1 h at 37
 
8
 
C. After four
additional washes, peroxidase-conjugated goat anti–mouse IgG
(Tago, Camarillo, CA) was added and incubated for 1 h at 37
 
8
 
C.
Antibody binding was visualized using orthophenylenediamine
(Sigma Chemical Co., St. Louis, MO) dissolved in citrate buffer
(pH 5) containing 0.012% H
 
2
 
O
 
2
 
; color was developed for 5–10
min. The optical density at 450 nm was measured using a micro-
plate reader (Molecular Devices, Sunnyvale, CA). A standard se-
rum composed of a mixture of sera from arthritic mice was added
to each plate in serial dilutions to establish a standard curve. The
standard serum was defined as 100 U and antibody titers of serum
samples were calculated from this standard curve by Softmax soft-
ware (Molecular Devices).
 
Histological Examination.
 
To evaluate the histology of joints,
mice were killed at 7–8 wk after immunization. Inflamed toes or
random toes (when macroscopic inflammation was not observed)
were excised, fixed in 10% buffered formalin, decalcified in
EDTA, embedded in paraffin, sectioned, and stained with hema-
toxylin and eosin.
 
IFN-
 
g
 
 Production of Lymph Node Cells.
 
IRF-1
 
1
 
/
 
2
 
 and IRF-1
 
2
 
/
 
2
 
DBA/1 mice were killed 14 or 21 d after initial immunization.
Lymph nodes (inguinal, paraaortic, axillary, and popliteal) were
removed, and cells were resuspended in DMEM supplemented
with 5 
 
3
 
 10
 
2
 
5
 
 M 2-mercaptoethanol, 20 mM Hepes, and 4% au-
tologous mouse serum. Cells were seeded at 4 
 
3
 
 10
 
6
 
/plate in 96-
well flat-bottomed microtiter plates (Nunc) and stimulated with
denatured bovine CII at 200 
 
m
 
g/ml or with purified anti-CD3
(2C11; PharMingen, San Diego, CA) at 5 
 
m
 
g/ml. For denatur-
ation, CII was dissolved in 0.1 M acetic acid, dialyzed against
DMEM for 48 h, and heat-denatured for 15 min at 56
 
8
 
C. Plated
cells were incubated at 37
 
8
 
C in 5% CO
 
2
 
 for 48 h, after which
culture supernatants were collected. IFN-
 
g
 
 was measured using
an ELISA kit (Genzyme, Cambridge, MA) according to the man-
ufacturer’s instructions.
 
Proinflammatory Cytokine Production of Peritoneal Macrophages.
 
Peritoneal macrophages from IRF-1
 
1
 
/
 
2
 
 and IRF-1
 
2
 
/
 
2
 
 DBA/1
mice were obtained 3 d after injection of thioglycolate. Cells were
resuspended in DMEM with 10% FCS at 2 
 
3
 
 10
 
6
 
/ml and seeded
in 24-well plates (1 ml/well). After 2-h incubation at 37
 
8
 
C, non-
adherent cells were removed by gentle washing with PBS. The
total peritoneal cell population and nonadherent cell population
were checked by surface staining of cells with anti-CD11b and
anti-B220 antibodies (PharMingen) to ensure that cell popula-
tions from IRF-1
 
1
 
/
 
2
 
 and IRF-1
 
2
 
/
 
2
 
 DBA/1 mice were compara-
ble. Adherent macrophages were stimulated with 1 
 
m
 
g/ml LPS
(Sigma), or 0.1 
 
m
 
g/ml LPS plus 100 U/ml IFN-
 
g
 
 (Genzyme), for
3 h and supernatants were collected for measurement of TNF-
 
a
 
.
Cells were then washed with DMEM, stimulated with 30 
 
m
 
M of
nigericin (Sigma) at 37
 
8
 
C for 30 min, and supernatants were col-
lected to measure IL-1
 
a
 
 and IL-1
 
b
 
. Cytokine concentrations
were determined with ELISA kits (Genzyme). IL-1
 
b
 
 could not
be detected in the supernatant before nigericin addition. Viability
of cells as judged by the trypan blue exclusion test was more than
95% after treatment with nigericin.
 
Adoptive Transfer of Arthritis Using a CII-specific T Cell Line and
Sera from Arthritic Mice.
 
A CII-specific T cell line was established
from CD4-deficient mice (24). These cells respond to denatured
CII (dCII) and native CII (nCII) in MHC-restricted (H-2
 
q
 
) fashion,
and the majority of cells have a phenotype of TCR
 
ab
 
1
 
 CD4
 
2
 
CD8
 
2
 
 (24). Sera from arthritic DBA/1 mice were pooled, pre-
cipitated with saturated ammonium sulfate (50% vol/vol), resus-
pended in PBS, and dialyzed against PBS for 2 d. Final volume
was 40–50% of the original sera. Anti-CII antibody level was mea-
sured as described above. On day 0, mice were injected intrave-
nously with 0.3 ml of concentrated sera containing 4–4.5 
 
3
 
 10
 
7
 
cells that had been stimulated with dCII for 3 d. Mice received a
second injection of sera (0.2 ml) on day 2. Mice were examined
and scored for signs of arthritis daily. Because almost all mice de-
veloped only mild disease (grade 1), the severity of arthritis was
measured by counting the number of fingers and toes that devel-
oped inflammation.
 
Induction of EAE.
 
Mice were immunized intradermally at the
base of the tail with 200 
 
m
 
g of rabbit myelin basic protein (Sigma)
emulsified with CFA on day 0. In addition, 200 ng of pertussis
toxin (List Biochemical Research, Campbell, CA) was injected
intravenously on days 0 and 2. Immunized mice were examined
daily and scored as previously described (25).
 
RT-PCR.
 
Total RNA was prepared from spinal cord and
joint tissue. Before removing spinal cords, mice were anesthetized
and perfused with 5 ml of PBS to reduce contamination with pe-
ripheral leukocytes. Joint tissue was prepared from soft tissues 
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around the ankle joint. Total RNA was extracted with TRI-ZOL
Reagent (GIBCO BRL, Gaithersburg, MD). cDNA was ob-
tained by reverse transcription of 2 
 
m
 
g of total RNA using oligo-
dT and a RT-PCR kit (Stratagene, La Jolla, CA). The manufac-
turer’s protocol was followed, using 10% of the reaction sample as
the template for PCR. Primers used were as follows: IRF-1,
GGTCAGAGACCCAAACTATGGTGC and TCTGAGTGG-
CATATGCAGATGGAC; 
 
b
 
-actin, ACCCACACTGTGCCC-
ATCTA and CGGAACCGCTCATTGCC; iNOS, CCCTTC-
CGAAGTTTCTGGCAGCAGCGGC and GGCTGTCAGAGC-
CTCGTGGCTTTGG (26). Reaction conditions for amplification
with PCR were the following: 94
 
8
 
C for 40 s; 56
 
8
 
C for 1 min;
72
 
8
 
C for 2 min. The detection of IRF-1 and 
 
b
 
-actin mRNAs re-
quired 24–30 PCR cycles. IRF-1 signals in the normal spinal
cord and normal joint tissues could usually be detected after 26
 
cycles of amplification, while detection of iNOS mRNA re-
quired 36 cycles. PCR products were separated on 2% agarose
gels and visualized with ethidium bromide.
 
Statistics.
 
Statistical significance of differences in incidence of
CIA or EAE, number of arthritic paws, and number of arthritic
fingers and toes were determined using 
 
x
 
2
 
 analysis. Student’s 
 
t test
was used to compare the arthritis index in CIA, severity in EAE,
and cytokine production in T cells and macrophages.
Results
Clinical Course of CIA in IRF-12/2 DBA/1 Mice.
IRF-12/2 and IRF-11/2 littermates were immunized with
CII and observed for signs of arthritis for up to 10 wk after
immunization. Disease incidence and the maximal ar-
thritis index were assessed at the end of this period. The
incidence of arthritis calculated from four independent ex-
periments is shown in Fig. 1 A. As shown in Table 1, the in-
cidence in IRF-12/2 mice (37.9%, 11 out of 29 mice) was
significantly decreased as compared with IRF-11/2 mice
(82.6%, 19 out of 23 mice; P ,0.005). There was also a
delay in the development of disease in IRF-12/2 mice, be-
cause the median day of onset among diseased individuals
was day 34 in IRF-11/2 mice, and day 44 in IRF-12/2
mice. Furthermore, the arthritis index (calculated only
from arthritic mice) was significantly decreased in IRF-12/2
mice (2.7 6 0.6) compared with IRF-11/2 mice (6.9 6 0.7;
P ,0.01) throughout the course of disease (Fig. 1 B). His-
tological examination of the phalangeal joints of toes of 4
out of 5 IFR-11/2 mice showed typical arthritis, character-
ized by dense cellular infiltration and bone erosion (Fig. 2
A). In contrast, most joints of IRF-12/2 mice (6 out of 7
mice) showed either mild infiltration of cells or no sign of
inflammation (Fig. 2 B). These data imply that the incidence
and the severity of CIA is decreased in IRF-12/2 mice;
however, there was no difference in anti-CII IgG antibody
level between the two groups of mice at 5 wk after immuni-
zation (IRF-11/2, 60 6 10 U; IRF-12/2, 52 6 12 U).
IFN-g Production of LN Cells from IRF-11/2 and IRF-12/2
DBA/1 Mice. To analyze the antigen-specific T cell re-
sponse in IRF-11/2 and IRF-12/2 DBA/1 mice, IFN-g
production by LN cells in response to dCII was examined.
Mice were killed at 14 or 21 d after immunization, and LN
cells were purified and stimulated with dCII or anti-CD3
antibodies. Anti-CD3 stimulation induced large amounts of
IFN-g secretion from LN cells in both groups of mice.
However, as shown in Fig. 3, LN cells from IRF-12/2
mice secreted a reduced amount of IFN-g in response to
dCII as compared with IRF-11/2 mice on day 14. On day
21, IFN-g production in response to dCII was decreased in
IRF-11/2 mice, while it remained at low levels in IRF-12/2
mice. These results suggest that IFN-g production by LN
cells in response to dCII is defective in IRF-12/2 mice.
Proinflammatory Cytokine Production of Peritoneal Macro-
phages from IRF-12/2 DBA/1 Mice. Macrophages produce
proinflammatory cytokines, such as IL-1 or TNF-a, which
have been shown to be important factors in perpetuating
arthritis (27–29). Recent studies have shown that IRF-1
Figure 1. Development of CIA in IRF-11/2 and IRF-12/2 DBA/1
mice. IRF-11/2 (squares, n 5 23) and IRF-12/2 (circles, n 5 29) mice
were immunized with bovine CII and signs of arthritis were monitored as
described in Materials and Methods. A summary of four experiments is
shown. (A) Incidence of arthritis in IRF-12/2 mice was decreased as
compared with that of control IRF-11/2 mice (P ,0.005). (B) Arthritis
index, calculated from arthritic mice only, was also decreased in IRF-12/2
mice after day 42 (P ,0.05). Mean arthritis index 6 SEM is shown.234 Autoimmune Diseases in Interferon Regulatory Factor-1-deficient Mice
regulates the induction of ICE in splenocytes (21). To test
the ability of macrophages from IRF-12/2 mice to secrete
these cytokines, peritoneal macrophages from IRF-11/2
and IRF-12/2 mice were stimulated with LPS (1 mg/ml),
or with LPS (0.1 mg/ml) plus IFN-g (100 U), and secreted
cytokine levels were measured by ELISA. There were no
differences in the amounts of secreted IL-1a, IL-1b, or
TNF-a detected after stimulation with LPS, or LPS plus
IFN-g, between macrophages of IRF-11/2 and IRF-12/2
mice (Table 2).
Adoptive Transfer of Arthritis in IRF-11/2 and IRF-12/2
DBA/1 Mice by a CII-specific T Cell Line and Sera from Ar-
thritic Mice. Because IRF-1 appeared to be involved in
both the induction and the the effector phases of CIA, the
effector phase of CIA in IRF-12/2 mice was examined by
adoptive transfer. Adoptive transfer of disease has been used
in the EAE model and in nonobese diabetes (NOD) mice,
but there is no established regimen for CIA. We evaluated
a method for adoptive transfer of CIA in which a CII-spe-
cific T cell line (established as described in Materials and
Methods), together with sera from arthritic mice, is in-
jected into naive DBA/1 mice. The helper T cells and anti-
CII antibodies required for the initiation of arthritis are in-
jected, while the macrophages and other effector cells are
derived from the recipient. Recipient mice developed mild
and transient arthritis, which was generally grade 1 in se-
verity (per paw). After day 10–14, these mice either devel-
oped stable arthritis, or underwent remission. As shown in
Fig. 4 A, the arthritis index in IRF-12/2 mice decreased as
compared with that in control IRF-11/2 mice after day 7.
The number of arthritic fingers and toes was also lower,
confirming the decreased severity of disease in IRF-12/2
mice (Fig. 4 B). These results suggest that IRF-12/2 mice
develop less severe arthritis than their IRF-11/2 counter-
parts, even in the presence of equal numbers of CII-specific
T cells and anti-CII antibodies.
EAE in IRF-12/2 PL/J Mice. We investigated a second
antigen–induced autoimmune disease model, EAE, in
IRF-12/2 mice. Mice were injected with myelin basic pro-
tein in CFA and pertussis toxin, and observed for signs of
disease. As shown in Table 3, the incidence of EAE was
significantly decreased in IRF-12/2 mice (P ,0.005).
However, 3 out of 4 IRF-12/2 mice that developed the
disease showed moderate to significant severity (maximal
scores were 1, 2.5, 3.5, and 3.5). The mean maximal score
calculated from diseased mice only was similar for IRF-11/2
and IRF-12/2 mice (IRF-11/2, 3.3 6 1.0; IRF-12/2, 2.6 6
1.2; Table 3).
Expression of IRF-1 and iNOS mRNA in Spinal Cord and
Joint Tissue. IRF-1 plays an important role in the induc-
tion of iNOS (9–11), and the resulting NO production in
macrophages and other cells is considered to be crucial in
promoting inflammation (12). To examine the expression
of IRF-1 and iNOS in inflamed tissues, RT-PCR of
mRNA from spinal cord (EAE) and joint tissue (CIA) of
IRF-11/2 mice with or without clinical disease was carried
out. IRF-1 mRNA was detected both in normal spinal
cord (Fig. 5, lanes 2 and 3), and in cells from spinal cords
with clinical EAE (lane 4, score 3.5; lane 5, score 4). In
fact, IFR-1 expression was enhanced in the latter, suggest-
ing an upregulation of IRF-1 mRNA in infiltrating cells
and/or resident cells in EAE spinal cord. iNOS mRNA ex-
pression was also detected in spinal cords of IRF-11/2 mice
with EAE (Fig. 5, lanes 4 and 5). In contrast, IRF-1 ex-
pression was not detected in IRF-12/2 mice with clinical
EAE (Fig. 5, lane 6, score 2.5; lane 7, score 3.5). However,
iNOS mRNA was observed in an IRF-12/2 mouse with
Figure 2. Histological exami-
nation of the joints from IRF-
11/2 and IRF-12/2 DBA/1
mice. Cellular infiltrate in the
synovium and erosion of carti-
lage and bone were observed in
joints from control IRF-11/2
DBA/1  mice (A). In contrast,
limited infiltration of cells was
detected in IRF-12/2 DBA/1
mice (B). Sections were excised
from CII-immunized mice at 7–8
wk after immunization and stained
with hematoxylin and eosin.
(350).
Figure 3. IFN-g production of LN cells from CII-immunized IRF-
11/2 and IRF-12/2 DBA/1 mice. LN cells were prepared on day 14 or
day 21 after immunization and stimulated with dCII or anti-CD3. IFN-g
production on day 14 was decreased by fourfold in IRF-12/2 mice (P
,0.05). Mean IFN-g concentration 6 SD from four (day 14) and two
(day 21) experiments is shown.235 Tada et al.
moderate EAE (Fig. 5, lane 6), which suggests that iNOS
can be induced by an IRF-1-independent pathway. Cau-
tion should be exercised in interpreting this result, since
.30 cycles of PCR were required to detect expression. In
the case of CIA, similar levels of IRF-1 and iNOS mRNA
expression were observed in four normal and two arthritic
(severity grade 2) IRF-11/2 mice. However, no iNOS signal
could be detected in joints from the three arthritic IRF-12/2
mice (two grade 1 and one grade 2).
Discussion
IRF-1 was originally identified by its ability to induce
the transcription of type I IFN and IFN-induced genes. Al-
though the expression of type I IFN and IFN-induced
genes was generally unimpaired in IRF-1-deficient mice
(6, 11), recent studies have revealed that IRF-1 is involved
in the regulation of other important genes and cellular
functions, such as iNOS and NO production (9, 10), and
ICE- and DNA damage–induced apoptosis (21). In the
present study, we investigated the role of IRF-1 in inflam-
mation and autoimmunity in two antigen-induced autoim-
mune disease models, CIA and EAE. Our data show that the
incidence of CIA was significantly decreased in IRF-12/2
DBA/1 mice; furthermore, arthritic IRF-12/2 mice
showed a milder disease than did IRF-11/2 mice. The sup-
pression of CIA in IRF-12/2 mice was more dramatic than
that reported in CD4- or CD8-deficient mice (24) or in
TNF-receptor p55-deficient mice (our unpublished obser-
vation). In the EAE model, IRF-12/2 PL/J mice were less
susceptible to EAE than IRF-11/2 PL/J mice, yet the EAE
that developed in IRF-12/2 mice was as severe as that in
the control mice. These results suggest that IRF-1 func-
tions as a proinflammatory factor in these disease models.
In this study, IRF-12/2 DBA/1 mice exhibited de-
creased IFN-g production in LN cells after immunization
with CII. This result could explain the lower incidence of
CIA in IRF-12/2 mice, although it is not clear whether
this low IFN-g response was attributable to T cells or to
antigen-presenting cells. To bypass the primary immune
responses against CII, we adoptively transferred disease into
naive IRF-11/2 and IRF-12/2 mice by injecting a CII-
Table 1. CIA in IRF-11/2 and IRF-12/2 DBA/1 Mice
Mouse
genotype Incidence of arthritis Arthritis index*
Number of
arthritic paws‡
Anti-CII IgG
antibody (U)
IRF-11/2 19/23 (82.6%) 6.9 6 0.7 56/92 (60.9%) 60 6 10
IRF-12/2 11/29 (37.9%)§ 2.7 6 0.6i 20/116 (17.2%)§ 52 6 12
*Mean 6 SEM of the maximal scores of arthritic mice is shown.
‡Number of paws with arthritis per total paws of immunized mice.
§P ,0.005 (x2 analysis).
iP ,0.01 (Student’s t test).
Table 2. Proinflammatory Cytokine Production of Peritoneal 
Macrophages from IRF-1/2 and IRF-12/2 DBA/1 Mice*
Stimulant/mouse
genotype
IL-1a
(ng/ml)
IL-1b
(pg/ml)
TNF-a
(ng/ml)
LPS (1 mg/ml)
IRF-11/2 0.56 6 0.06‡ 71 6 53 5.4 6 0.5
IRF-12/2 0.71 6 0.19 75 6 21 4.4 6 1.5
LPS (0.1 mg/ml) 1
IFN-g (100 U)
IRF-11/2 0.22 6 0.01 56 6 22 10.9 6 0.8
IRF-12/2 0.23 6 0.05 42 6 23 8.4 6 0.8
*Peritoneal macrophages were stimulated with LPS, or LPS plus IFN-g,
for 3 h. IL-1 secretion was further induced by stimulating cells with
nigericin as described in Materials and Methods. A representative result
from three independent experiments is shown. Each experiment in-
cluded 2–3 mice per group.
‡Mean 6 SD is shown.
Figure 4. Adoptive transfer of arthritis in IRF-11/2 and IRF-12/2
DBA/1 mice. A CII-reactive cell line together with sera from arthritic
mice was injected into naive mice as described in Materials and Methods.
Arthritis index (A), and number of fingers and toes with arthritis (B), were
evaluated. Arthritis index and number of arthritic fingers and toes were
decreased in IRF-12/2 mice (circles) after day 7 (P ,0.05 and P ,0.01, re-
spectively) as compared with those in IRF-11/2 mice (squares). In this ex-
periment, all IRF-11/2 and IRF-12/2 mice developed arthritis. A repre-
sentative result from a total of three experiments is shown.236 Autoimmune Diseases in Interferon Regulatory Factor-1-deficient Mice
specific T cell line together with sera from arthritic mice,
thereby mimicking the cellular and humoral responses
against against CII immunization. The results showed that
disease development in IRF-12/2 mice after adoptive transfer
was still impaired. These data suggest that effector cells other
than CII-specific helper T cells, or cellular components of the
autoimmune target organ, may limit disease progression.
It has been shown that neither CD41 T cells (30, 31) nor
TCRab1 T cells (31) are required to maintain CIA after its
onset. These results taken together with the finding that
the majority of infiltrating cells in inflamed joints are mac-
rophages (32, 33), suggest that the principal force driving
CIA after onset may be derived from macrophages. We
speculate that the decreased disease severity in IRF-12/2
mice after adoptive transfer may be partly due to decreased
proinflammatory functions of effector cells, presumably
macrophages, in IRF-1-deficient mice. Cytokine secretion
of peritoneal macrophages from IRF-12/2 mice in re-
sponse to LPS, or LPS with IFN-g, was normal. Although
this result does not necessarily indicate that cytokine pro-
duction in macrophages is intact in IRF-12/2 mice with
CIA, normal levels of proinflammatory cytokines were
produced in response to certain stimuli. It is also possible
that activation of synovial cells or endothelial cells resulting
in cytokine production or adhesion molecule expression
might be deregulated in the absence of IRF-1. In contrast
with the mild disease exhibited in the CIA experiment,
IRF-12/2 mice that developed EAE showed severities sim-
ilar to those in IRF-11/2 mice, although only a small num-
ber of mice developed clinical disease. This suggests that
the role of IRF-1 may be less important in the disease pro-
gression of EAE than in CIA.
NO exerts a plethora of effects on a variety of cells and
tissues, including the modification of enzymes and tran-
scription factors that result in modulated cellular responses
(12, 34). A role for NO in rheumatoid arthritis was sug-
gested by the finding that the NO catabolite nitrite is in-
creased in the synovial fluid and sera of patients (35). In ad-
dition, NO and iNOS were identified in the spinal cords of
mice with EAE (18–20). These results are confirmed in this
study because iNOS was expressed in the spinal cord of
mice with EAE and in the joint tissue of mice with CIA.
Inhibitors of iNOS can suppress some autoimmune disease
models in rodents, including streptococcal cell wall frag-
ment–induced rat arthritis (15), murine lupus (16), and
murine EAE (17). It has been shown previously that IRF-1
regulates iNOS, and that macrophages from IRF-12/2
mice produce little NO (6, 11). Therefore, it is conceivable
that the decreased iNOS mRNA induction and subsequent
NO production observed in macrophages of IRF-12/2
mice contribute to the suppression of CIA and EAE disease
in these animals.
IRF-1 mRNA expression was found to be increased in
Table 3. EAE in IRF-11/2 and IRF-12/2 PL/J Mice
Mouse genotype Incidence of disease Severity* (total mice) Severity‡ (diseased mice) Day of onset
IRF-11/2 12/15 (80.0%) 2.6 6 0.4 3.3 6 0.3 25.8 6 2.1
IRF-12/2 4/13 (30.8%)§ 0.8 6 0.3i 2.6 6 0.5 30.3 6 1.4
*Mean 6 SEM of the maximal scores of total mice is shown.
‡Mean 6 SEM of the maximal scores of diseased mice is shown.
§P ,0.005 (x2 analysis),
iP ,0.005 (Student’s t test).
Figure 5. RT-PCR study of IRF-1 (A) and iNOS (C) mRNA expres-
sion in spinal cords from IRF-11/2 (lanes 2–5) and IRF-12/2 (lanes 6 and 7)
PL/J mice with (lanes 4–7) or without (lanes 2 and 3) clinical EAE. Lane 1
is a DNA size marker (fx174 DNA digested with HaeIII). IRF-1 expres-
sion was detected in normal spinal cord (lanes 2 and 3) and was increased
in the spinal cords of IRF-11/2 mice with EAE (lanes 4 and 5). No PCR
product was observed in IRF-12/2 samples (lanes 6 and 7). iNOS mRNA
was detected in spinal cords from IRF-11/2 (lanes 4 and 5) and IRF-12/2
(lane 6) mice with EAE. PCR reactions were run 26 cycles for IRF-1 and
b-actin, and 36 cycles for iNOS. Clinical scores at the time of tissue prep-
aration were the following: lane 4, grade 3.5; lane 5, grade 4; lane 6,
grade 2.5; lane 7, grade 3.5.237 Tada et al.
the spinal cords of IRF-11/2 mice with EAE. Upregulation
of IRF-1 mRNA in the spinal cord suggests the activation
of infiltrating inflammatory cells and/or resident glial cells.
Because NO in the spinal cord is thought to be derived
from microglia and infiltrating macrophages (36–38), up-
regulation of IRF-1, presumably in response to cytokines
from T cells and macrophages, might lead to the expression
of iNOS mRNA and subsequent NO production in these
cells. However, we also observed iNOS expression in an
IRF-12/2 mouse with EAE, suggesting that iNOS can be
induced by an IRF-1-independent pathway.
ICE plays a role in IL-1b secretion by processing the
precursor form of IL-1b intracellularly to mature bioactive
IL-1b (39, 40). ICE-deficient mice showed no IL-1b se-
cretion and markedly reduced IL-1a secretion in mono-
cytes and macrophages (22, 23). In this study, no differ-
ences in IL-1a, IL-1b, and TNF-a secretion between
IRF-12/2 and IRF-11/2 macrophages were observed. These
data seem to contradict a previous report in which IRF-1
was found to regulate the induction of ICE (21). Although
the precise mechanism remains to be elucidated, basal ex-
pression of ICE might be sufficient to induce secretion of
mature IL-1b in macrophages. Alternatively, the use of dif-
ferent cells and stimulants in these experiments (splenocytes
versus peritoneal macrophages, Con A versus LPS and
IFN-g) might produce different activation profiles.
It has been shown that IRF-1-deficient mice have only
70% of the number of CD81 T cells present in IRF-11/2
mice (6). However, it is unlikely that the low number of
CD81 T cells prevented the development of CIA and EAE
disease in IRF-1-deficient mice. In previous experiments
with CD8-deficient mice, the incidence of EAE was found
to be normal (25). The incidence of CIA in CD8-deficient
mice was decreased (50%) relative to controls (84.2%), but
the severity of the disease was similar (24).
Since the critical role of IRF-1 in iNOS induction was
discovered, IRF-1 has been targeted as a therapeutic agent
with an eye to regulating NO production and NO-induced
toxicity. Our data provide further evidence that IRF-1 is
important in inflammation and autoimmunity in in vivo
murine disease models. The loss of IRF-1 affects both the
antigen-priming phase and the effector phase in CIA dis-
ease. The proinflammatory function of IRF-1 may not be
limited to iNOS induction and may include the regulation
of other molecules. Although the exact mechanisms have
yet to be determined, these results indicate that the modu-
lation of IRF-1 could be an effective strategy in mitigating
inflammation and autoimmune disease.
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